Premium
Induction of prostate tumor‐specific CD8 + cytotoxic T‐lymphocytes in vitro using antigen‐presenting cells pulsed with prostatic acid phosphatase peptide
Author(s) -
Peshwa Madhusudan V.,
Shi Jia Dong,
Ruegg Curtis,
Laus Reiner,
van Schooten Wim C.A.
Publication year - 1998
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(19980701)36:2<129::aid-pros8>3.0.co;2-d
Subject(s) - cytotoxic t cell , prostatic acid phosphatase , in vitro , peptide , antigen , prostate specific antigen , prostate , cancer research , cd8 , t lymphocyte , medicine , immunology , chemistry , biology , biochemistry , cancer
Abstract BACKGROUND Most strategies in cancer immunotherapy are aimed at the induction of a strong cellular immune response against the tumor. Particularly, CD8 + T lymphocytes have been proven in multiple animal models to be critical for the eradication of solid tumors. METHODS We used a population of peripheral blood‐derived antigen‐presenting cells (APC), containing dendritic cells (DC), to generate prostate tumor‐specific CD8 + T cells. Selected peptides from prostatic acid phosphatase (PAP), a prostate tissue‐specific antigen, were shown to bind HLA‐A2. A high‐affinity peptide was used to generate peptide‐specific CD8 + cytolytic T lymphocytes (CTL) from the peripheral blood of healthy donors. RESULTS The obtained PAP‐peptide‐specific CTL lysed peptide‐coated target cells, vaccinia‐infected target cells, and HLA‐A2‐positive prostate‐tumor cells in vitro in an antigen‐specific manner. CONCLUSIONS Our results indicate that CTL precursors to the PAP gene product exist and could be potentially recruited to elicit an antitumor response. Thus, PAP is a suitable antigen for inclusion in prostate cancer vaccines. Prostate 36:129–138, 1998. © 1998 Wiley‐Liss, Inc.